Elicera Therapeutics AB (publ) (ELIC.ST)
SEK 1.71
(-0.29%)
SEK 1.71
(-0.29%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 11.23 Million SEK | 777.23% |
| 2022 | 1.28 Million SEK | 217987.39% |
| 2021 | 587.00 SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.03 Million SEK | 10859.19% |
| 2024 Q2 | 988.7 Thousand SEK | -67.42% |
| 2023 Q4 | 27.69 Thousand SEK | -99.65% |
| 2023 Q3 | 8.01 Million SEK | 352.74% |
| 2023 FY | 11.23 Million SEK | 777.23% |
| 2023 Q1 | 1.41 Million SEK | 167.66% |
| 2023 Q2 | 1.77 Million SEK | 25.52% |
| 2022 Q2 | 2673.00 SEK | -99.29% |
| 2022 Q1 | 374.59 Thousand SEK | 63715.16% |
| 2022 FY | 1.28 Million SEK | 217987.39% |
| 2022 Q4 | 527.22 Thousand SEK | 40.34% |
| 2022 Q3 | 375.68 Thousand SEK | 13954.73% |
| 2021 Q3 | 106.00 SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 FY | 587.00 SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 Q4 | 587.00 SEK | 453.77% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 80.673% |
| Ziccum AB (publ) | 3.74 Million SEK | -199.708% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 98.177% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 77.756% |
| Mendus AB (publ) | 28.48 Million SEK | 60.578% |
| Genovis AB (publ.) | 158.23 Million SEK | 92.903% |
| Intervacc AB (publ) | 8.01 Million SEK | -40.113% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -156.746% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 93.411% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 74.417% |
| Aptahem AB (publ) | 2.63 Million SEK | -326.893% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -985.03% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -14484.497% |
| Fluicell AB (publ) | 3.33 Million SEK | -236.431% |
| Saniona AB (publ) | 16.84 Million SEK | 33.313% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 31.553% |
| Biovica International AB (publ) | 7.29 Million SEK | -54.048% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -833.505% |
| AcouSort AB (publ) | 10.55 Million SEK | -6.436% |
| Xintela AB (publ) | 78 Thousand SEK | -14297.517% |
| Abliva AB (publ) | 137 Thousand SEK | -8097.126% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 80.503% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -457.6% |
| OncoZenge AB (publ) | 3000.00 SEK | -374235.433% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -7145.202% |
| CombiGene AB (publ) | 5.54 Million SEK | -102.558% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.07% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.346% |
| Corline Biomedical AB | 25.03 Million SEK | 55.134% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -97.782% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -1457.568% |
| I-Tech AB | 120.86 Million SEK | 90.708% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 91.625% |
| Cyxone AB (publ) | 5.14 Million SEK | -118.144% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -59.292% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -5.301% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 1.44 Million SEK | -678.244% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -21088.798% |
| BioInvent International AB (publ) | 71.46 Million SEK | 84.285% |
| Alzinova AB (publ) | 270 Thousand SEK | -4059.283% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 68.115% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -667.595% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -297.947% |
| Simris Alg AB (publ) | 4.35 Million SEK | -157.925% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -8538.51% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 95.296% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -48726.361% |